NCT00163280 - Safety, Tolerability and Efficacy of ATL-104 in Oral Mucositis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions

Mucositis

Interventions

DRUG

ATL-104

Daily does of ATL-104 (50,100 or 150mg) or placebo for 3 days prior to the start of chemotherapy and peripheral blood stem cell transplantation. Following stem cell transplantation patients received 3 further daily doses of ATL-104 (50, 100 or 150mg) or placebo.

Trial Locations (8)

Unknown

Research Site, Birmingham

Research Site, Cambridge

Research Site, Cardiff

Research Site, Leeds

Research Site, Leicester

Research Site, London

Research Site, Oxford

Research Site, Plymouth